Collegium Pharmaceutical, Inc. COLL

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 46.7% gain over the past six months, beating the S&P 500 by 25.6 percentage points.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences: Morgan Stanley 24th Annual Global Healthcare ConferenceFireside Chat Date and Time: Tuesday, September 15, 2026, at 4:05 p.m. ETNew York, NY H.C. Wainwright 28th Annual Global

Collegium Pharmaceutical’s second quarter saw sales growth, but results missed Wall Street’s revenue expectations, leading to a negative market reaction. Management attributed top-line growth to the expansion of its ADHD business, notably Jornay PM’s 41% year-over-year revenue increase and broader prescriber reach. CEO Vikram Karnani stressed that the integration of recently acquired Azstarys was completed ahead of the crucial back-to-school season, reinforcing the company’s strategy to diversif

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year to $199.9 million. The company’s full-year revenue guidance of $840 million at the midpoint came in 3.4% below analysts’ estimates. Its non-GAAP profit of $1.92 per share was 8.8% above analysts’ consensus estimates.

Moby summary of Collegium Pharmaceutical, Inc.'s Q2 2026 earnings call

Strong ADHD growth offsets pain portfolio pressure, with total revenues up 6% and adjusted EBITDA rising 8% year-over-year.

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +14.29% and +1.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year to $199.9 million. The company’s full-year revenue guidance of $840 million at the midpoint came in 3.4% below analysts’ estimates. Its non-GAAP profit of $1.92 per share was 8.8% above analysts’ consensus estimates.

– Completed Acquisition of AZSTARYS®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year – – Generated AZSTARYS Quarterly Net Revenue of $12.9 Million, Representing a Partial Quarter of Sales – – Generated Quarterly Pain Portfolio Net Revenues of $140.9 Million – – Updates Full-Year 2026 Financial Guidance – – Confer

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.